A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
Status:
Withdrawn
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of GS-9411 in patients
with Cystic Fibrosis. GS-9411 is a sodium channel inhibitor, that may restore airway
hydration and mucociliary clearance in the lung.